Intérêt de la toxine botulinique de type A dans le traitement des syndromes de Raynaud sévères secondaires à la sclérodermie systémique-Reference-Cited by-同舟云学术

Intérêt de la toxine botulinique de type A dans le traitement des syndromes de Raynaud sévères secondaires à la sclérodermie systémique

Published:2013-12 Issue:6 Volume:58 Page:658-662
ISSN:0294-1260
Container-title:Annales de Chirurgie Plastique Esthétique
language:fr
Short-container-title:Annales de Chirurgie Plastique Esthétique

Author:

Serri J.,Legré R.,Veit V.,Guardia C.,Gay A.-M.

Publisher

Elsevier BV

Subject

Surgery

Reference16 articles.

1. (1834–1881) Raynaud's disease;Maurice Raynaud;JAMA,1967

2. Episodic digital vasospasm--the legacy of Maurice Raynaud. Lancet 1977;1(8020):1039–40.

3. Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma;Hummers;Rheum Dis Clin North Am,2003

4. Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenon;Am Heart J,1991

5. Pope J, Fenlon D, Thompson A, et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000(2):CD000953.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toxin for Treating Raynaud Conditions in Hands (The TORCH Study): A Systematic Review and Meta-analysis;Plastic and Reconstructive Surgery - Global Open;2024-06

2. Botulinum Toxin Type A in the Treatment of Raynaud’s Syndrome: A Case Report;Cureus;2024-03-31

3. A Mechanistic Approach to Understanding and Preventing the Vasculopathy of Raynaud’s Phenomenon;Raynaud’s Phenomenon;2024

4. The Use of Botulinum Toxin in Raynaud Phenomenon;Annals of Plastic Surgery;2023-07

5. Efficacy of botulinum toxin type A injection for Raynaud’s phenomenon and digital ulcers in patients with systemic sclerosis;Rheumatology;2022-12-30